Research Output Journal of Public Health and Medicine 5(3):58-61, 2025

ROJPHM

ISSN ONLINE: 1115-9715
ISSN PRINT: 1115-6147

https://rojournals.org/roj-public-health-and-medicine/

https://doi.org/10.59298/ROJPHM/2025/535861



# Efficacy of Artificial Pancreas Systems vs. Standard Insulin Pump Therapy in Pregnant Women with Type 1 Diabetes

**Maina Mwaura F.**

**School of Natural and Applied Sciences Kampala International University Uganda**

## ABSTRACT

Pregnancy in women with Type 1 Diabetes Mellitus (T1DM) poses significant challenges, requiring stringent glycemic control to mitigate risks for both mother and fetus. This review evaluated the efficacy of Artificial Pancreas Systems (APS) compared to standard insulin pump therapy in pregnant women with T1DM, focusing on maternal glycemic control, neonatal outcomes, and patient satisfaction. APS, which integrates continuous glucose monitoring (CGM) with automated insulin delivery, has demonstrated superior glycemic control, evidenced by increased time-in-range (TIR), reduced HbA1c levels, and fewer hypoglycemic and hyperglycemic episodes. These improvements translate into better neonatal outcomes, including reduced rates of macrosomia, preterm birth, and neonatal hypoglycemia. Additionally, APS alleviates the burden of diabetes management, enhancing patient satisfaction and quality of life. However, challenges such as high costs, technical complexity, and the need for long-term safety data remain. This review synthesized evidence from recent studies, utilizing a systematic literature review methodology to provide a comprehensive analysis of APS efficacy. The findings highlighted APS as a transformative advancement in diabetes care during pregnancy, with the potential to improve maternal and neonatal outcomes significantly. Future research should focus on longitudinal studies to assess long-term impacts and strategies to enhance accessibility and usability, ensuring broader adoption of this promising technology.

**Keywords:** Artificial Pancreas Systems (APS), Type 1 Diabetes Mellitus (T1DM), Pregnancy, Glycemic Control, Neonatal Outcomes.

## INTRODUCTION

Pregnancy in women with Type 1 Diabetes Mellitus (T1DM) presents a complex clinical challenge, requiring meticulous glycemic control to minimize risks to both the mother and the developing fetus [1, 2]. Despite advances in diabetes management, pregnant women with T1DM remain at heightened risk for adverse outcomes, including preeclampsia, preterm birth, macrosomia, and neonatal hypoglycemia [3, 4]. Achieving optimal glycemic control, as measured by time-in-range (TIR) and HbA1c levels, is critical yet difficult due to the dynamic physiological changes that occur during pregnancy, such as increased insulin resistance and fluctuating insulin requirements. Traditional insulin pump therapy, specifically continuous subcutaneous insulin infusion (CSII), has been widely used to manage T1DM during pregnancy. However, the need for frequent manual adjustments and constant monitoring places a significant burden on patients, often leading to suboptimal glycemic control. The emergence of Artificial Pancreas Systems (APS), also known as closed-loop insulin delivery systems, represents a transformative advancement in diabetes care [5, 6]. APS integrates continuous glucose monitoring (CGM) with automated insulin delivery, providing real-time adjustments to insulin based on glucose levels. This technology has the potential to revolutionize diabetes management during pregnancy by improving glycemic control, reducing the burden of self-management, and enhancing patient satisfaction. Recent studies have demonstrated that APS significantly improves TIR and reduces the frequency of hypoglycemic and hyperglycemic episodes compared to standard insulin pump therapy. These improvements in glycemic control are expected to translate into better maternal and neonatal outcomes, including reduced rates of macrosomia, preterm birth, and neonatal hypoglycemia. Pregnancy in women with

T1DM is associated with increased insulin resistance, fluctuating insulin requirements, and heightened glycemic variability [7, 8]. These factors complicate diabetes management and increase the risk of maternal and fetal complications. Standard insulin pump therapy, while effective, requires frequent manual adjustments and constant monitoring, placing a significant burden on patients. APS, which integrates continuous glucose monitoring (CGM) with automated insulin delivery, offers a promising solution by providing real-time adjustments to insulin delivery based on glucose levels. This technology has the potential to improve glycemic control and reduce the burden of diabetes management during pregnancy. This review aims to evaluate the efficacy of APS compared to standard insulin pump therapy in pregnant women with T1DM, focusing on maternal glycemic control, neonatal outcomes, and patient satisfaction. By synthesizing the latest evidence, this review seeks to provide a comprehensive understanding of the potential benefits and limitations of APS in this high-risk population, offering valuable insights for clinicians, researchers, and policymakers.



## MATERNAL GLYCEMIC CONTROL

Glycemic control is a critical determinant of pregnancy outcomes in women with T1DM [9, 10]. The primary metrics for assessing glycemic control include TIR, HbA1c levels, and the frequency of hypoglycemic and hyperglycemic episodes. Studies have demonstrated that APS significantly improves TIR compared to standard insulin pump therapy. For instance, APS has been shown to increase the percentage of time spent within the target glucose range (70-140 mg/dL) by an average of 10-15%, a clinically meaningful improvement. This enhancement in TIR is attributed to the system's ability to make real-time adjustments to insulin delivery, reducing the likelihood of prolonged hyperglycemia or hypoglycemia. HbA1c levels, which reflect long-term glycemic control, also tend to be lower in women using APS [11, 12]. The automated nature of APS minimizes the risk of human error in insulin dosing, leading to more stable glucose levels over time. Furthermore, APS has been associated with a reduction in the frequency and severity of hypoglycemic episodes, a common concern during pregnancy. Hypoglycemia can have detrimental effects on both the mother and the fetus, including impaired cognitive development and increased risk of congenital anomalies. By maintaining glucose levels within a narrower range, APS reduces the incidence of these adverse events.

## NEONATAL OUTCOMES

The benefits of improved maternal glycemic control extend to neonatal outcomes. Macrosomia, defined as a birth weight exceeding the 90th percentile for gestational age, is a common complication in pregnancies complicated by T1DM [13]. Excessive fetal growth is primarily driven by maternal hyperglycemia, which results in increased fetal insulin production and subsequent growth. APS has been shown to reduce the incidence of macrosomia by maintaining tighter glycemic control throughout pregnancy. This reduction in macrosomia is associated with a lower risk of birth injuries, such as shoulder dystocia, and a decreased likelihood of requiring cesarean delivery. Preterm birth, another significant concern in pregnancies complicated by T1DM, is also influenced by maternal glycemic control [14]. Women using APS have been observed to have a lower incidence of preterm birth compared to those using standard insulin pump therapy. This reduction is likely due to the improved stability of glucose levels, which minimizes the risk of placental dysfunction and other complications that can lead to preterm labor. Additionally, neonatal hypoglycemia, a common complication in infants born to mothers with T1DM, is less frequent in pregnancies managed with APS. The system's ability to prevent maternal hypoglycemia indirectly reduces the risk of neonatal hypoglycemia, as the fetus is less likely to experience episodes of low glucose levels in utero.

## PATIENT SATISFACTION AND QUALITY OF LIFE

Beyond clinical outcomes, patient satisfaction and quality of life are critical considerations in the management of T1DM during pregnancy. The burden of diabetes management can be overwhelming, particularly during pregnancy when the stakes are high. APS has been shown to significantly reduce the burden of diabetes management by automating insulin delivery and reducing the need for frequent manual adjustments. Women using APS report higher levels of satisfaction with their diabetes management and a greater sense of control over their condition [15, 16]. The psychological impact of diabetes management during pregnancy should not be underestimated. The constant need to monitor glucose levels and adjust insulin doses can lead to anxiety and stress, which can negatively impact maternal and fetal health [17, 18]. APS alleviates this burden by providing real-time feedback and automated adjustments, allowing women to focus on other aspects of their pregnancy. This improvement in quality of life is particularly important in a population already facing significant physical and emotional challenges.

## CHALLENGES AND LIMITATIONS

Despite the promising benefits of APS, there are several challenges and limitations to consider. The cost of APS is significantly higher than that of standard insulin pump therapy, which may limit access for some patients [19]. Additionally, technology requires a certain level of technical proficiency, which may be a barrier for older patients or those with limited experience with diabetes technology. Furthermore, while APS has been shown to improve

glycemic control, it is not a cure for diabetes and requires ongoing monitoring and adjustments by healthcare providers. Another limitation is the potential for device malfunctions or inaccuracies in glucose readings. While rare, these events can have serious consequences, particularly during pregnancy. Patients using APS must be educated on the importance of regular device maintenance and the need for backup insulin delivery methods in case of device failure. Additionally, the long-term safety and efficacy of APS in pregnant women have not been fully established, and further research is needed to address these concerns.



## FUTURE DIRECTIONS

The field of diabetes technology is rapidly evolving, and future advancements in APS are likely to address many of the current limitations. Improvements in CGM accuracy, insulin delivery algorithms, and user interface design are expected to enhance the efficacy and usability of APS [20]. Additionally, the integration of APS with other digital health tools, such as telemedicine platforms, has the potential to further improve diabetes management during pregnancy. Research is also needed to explore the impact of APS on long-term maternal and child health outcomes. While the short-term benefits of APS are well-documented, the long-term effects on maternal metabolic health and child development are less understood. Longitudinal studies following women and their children from pregnancy through childhood will provide valuable insights into the lasting impact of APS on health outcomes.

## CONCLUSION

The review underscores the transformative potential of Artificial Pancreas Systems (APS) in managing Type 1 Diabetes Mellitus (T1DM) during pregnancy, a period marked by heightened risks for both maternal and fetal health. Compared to standard insulin pump therapy, APS demonstrates superior efficacy in improving maternal glycemic control, as evidenced by increased time-in-range (TIR), reduced HbA1c levels, and fewer hypoglycemic and hyperglycemic episodes. These improvements translate into better neonatal outcomes, including reduced rates of macrosomia, preterm birth, and neonatal hypoglycemia, which are critical for ensuring the health and well-being of both mother and child. Additionally, APS significantly alleviates the burden of diabetes management, enhancing patient satisfaction and quality of life during an already challenging period. However, challenges such as high costs, technical complexity, and the need for long-term safety data remain barriers to widespread adoption. Despite these limitations, APS represents a promising advancement in diabetes care, with ongoing technological improvements likely to address current shortcomings. Future research should focus on longitudinal studies to evaluate the long-term maternal and child health outcomes associated with APS use, as well as strategies to improve accessibility and usability. As the field of diabetes technology continues to evolve, APS holds the potential to revolutionize the management of T1DM in pregnancy, offering hope for improved outcomes and a better quality of life for affected women and their families.

## REFERENCES


1. Stamati, A., Christoforidis, A.: Automated insulin delivery in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetologica 2025. 1–12 (2025). https://doi.org/10.1007/S00592-025-02446-X
2. Jeeyavudeen, M.S., Crosby, M., Pappachan, J.M.: Continuous glucose monitoring metrics in pregnancy with type 1 diabetes mellitus. World J Methodol. 14, 90316 (2024). https://doi.org/10.5662/WJM.V14.I1.90316
3. Atta, N., Ezeoke, A., Petry, C.J., Kusinski, L.C., Meek, C.L.: Associations of High BMI and Excessive Gestational Weight Gain With Pregnancy Outcomes in Women With Type 1 Diabetes: A Systematic Review and Meta-analysis. Diabetes Care. 47, 1855–1868 (2024). https://doi.org/10.2337/DC24-0725
4. Feldman, A.Z., Brown, F.M.: Management of Type 1 Diabetes in Pregnancy. Curr Diab Rep. 16, 1–13 (2016). https://doi.org/10.1007/S11892-016-0765-Z/TABLES/2
5. Mehmood, S., Ahmad, I., Arif, H., Ammara, U.E., Majeed, A.: Artificial Pancreas Control Strategies Used for Type 1 Diabetes Control and Treatment: A Comprehensive Analysis. Applied System Innovation 2020, Vol. 3, Page 31. 3, 31 (2020). https://doi.org/10.3390/ASI3030031
6. Ghosh, N., Verma, S.: Technological advancements in glucose monitoring and artificial pancreas systems for shaping diabetes care. Curr Med Res Opin. (2024). https://doi.org/10.1080/03007995.2024.2422005
7. Mastorakos, G., Suzuki, H., Papagianni, M., Raheli´c, D.R., Gitsi, E., Livadas, S., Angelopoulos, N., Paparodis, R.D., Raftopoulou, M., Argyrakopoulou, G.: A Nutritional Approach to Optimizing Pump Therapy in Type 1 Diabetes Mellitus. Nutrients 2023, Vol. 15, Page 4897. 15, 4897 (2023). https://doi.org/10.3390/NU15234897
8. Jaffar, F., Laycock, K., Huda, M.S.B.: Type 1 Diabetes in Pregnancy: A Review of Complications and Management. Curr Diabetes Rev. 18, (2021). https://doi.org/10.2174/1573399818666211105124829

9. Obeagu, E.I., Okechukwu, U., Alum, E.U.: Poor Glycaemic Control among Diabetic Patients: A Review on Associated Factors. (2023)
10. Kekäläinen, P., Juuti, M., Walle, T., Laatikainen, T.: Pregnancy planning in type 1 diabetic women improves glycemic control and pregnancy outcomes. The Journal of Maternal-Fetal & Neonatal Medicine. 29, 2252–2258 (2016). https://doi.org/10.3109/14767058.2015.1081888
11. Kovatchev, B.P.: Metrics for glycaemic control — from HbA1c to continuous glucose monitoring. Nature Reviews Endocrinology 2017 13:7. 13, 425–436 (2017). https://doi.org/10.1038/nrendo.2017.3
12. Reutrakul, S., Thakkinstian, A., Anothaisintawee, T., Chontong, S., Borel, A.L., Perfect, M.M., Janovsky, C.C.P.S., Kessler, R., Schultes, B., Harsch, I.A., van Dijk, M., Bouhassira, D., Matejko, B., Lipton, R.B., Suwannalai, P., Chirakalwasan, N., Schober, A.K., Knutson, K.L.: Sleep characteristics in type 1 diabetes and associations with glycemic control: systematic review and meta-analysis. Sleep Med. 23, 26–45 (2016). https://doi.org/10.1016/J.SLEEP.2016.03.019
13. Faaez Abdulnabi, S., Nikpayam, O., Ghorbani Gholiabad, S., Abedalnabi Flaifel, H., Ali Alatter, S., Mohammadi, M., Jabbari, A.: Association between Pregnancy-Associated Diabetes and Macrosomia: A Systematic Review and Meta-analysis. Journal of Clinical and Basic Research. 0–0. https://doi.org/10.29252/JCBR.8.4.10
14. Apata, T., Samuel, D., Valle, L., Crimmins, S.D.: Type 1 Diabetes and Pregnancy: Challenges in Glycemic Control and Maternal-Fetal Outcomes. Semin Reprod Med. 42, 239–248 (2024). https://doi.org/10.1055/S-0044-1791704/ID/BR2400023-24/BIB
15. Schipp, J., Skinner, T., Holloway, E., Scibilia, R., Langstrup, H., Speight, J., Hendrieckx, C.: How Adults with Type 1 Diabetes Are Navigating the Challenges of Open-Source Artificial Pancreas Systems: A Qualitative Study. https://home.liebertpub.com/dia. 23, 546–554 (2021). https://doi.org/10.1089/DIA.2020.0652
16. Sherr, J.L., Heinemann, L., Fleming, G.A., Bergenstal, R.M., Bruttomesso, D., Hanaire, H., Holl, R.W., Petrie, J.R., Peters, A.L., Evans, M.: Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetes Care. 45, 3058–3074 (2022). https://doi.org/10.2337/DCI22-0018
17. Lawton, J., Kimbell, B., Closs, M., Hartnell, S., Lee, T.T.M., Dover, A.R., Reynolds, R.M., Collett, C., Barnard-Kelly, K., Hovorka, R., Rankin, D., Murphy, H.R.: Listening to Women: Experiences of Using Closed-Loop in Type 1 Diabetes Pregnancy. Diabetes Technol Ther. 25, 845–855 (2023). https://doi.org/10.1089/DIA.2023.0323/SUPPL_FILE/SUPPL_FILE.DOCX
18. Ringholm, L., Damm, P., Mathiesen, E.R.: Improving pregnancy outcomes in women with diabetes mellitus: modern management. Nature Reviews Endocrinology 2019 15:7. 15, 406–416 (2019). https://doi.org/10.1038/s41574-019-0197-3
19. Jendle, J., Ericsson, Å., Gundgaard, J., Møller, J.B., Valentine, W.J., Hunt, B.: Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis. Diabetes Therapy. 12, 373–388 (2021). https://doi.org/10.1007/S13300-020-00980-1/TABLES/4
20. Yu, T.S., Song, S., Yea, J., Jang, K.-I.: Diabetes Management in Transition: Market Insights and Technological Advancements in CGM and Insulin Delivery. Advanced Sensor Research. 3, 2400048 (2024). https://doi.org/10.1002/ADSR.202400048


**CITE AS: Maina Mwaura F. (2025). Efficacy of Artificial Pancreas Systems vs. Standard Insulin Pump Therapy in Pregnant Women with Type 1 Diabetes. Research Output Journal of Public Health and Medicine 5(3):58-61. https://doi.org/10.59298/ROJPHM/2025/535861**